Tilray Brands spent the latest year proving it is no longer a single-country cannabis grower, and the proof arrived as a four-segment consumer platform that still cannot fund itself. Management closed the May year-end with record sales near $916 million and almost no net debt. The cash account held only because new shares were sold into a United States rescheduling headline. The investment debate is whether European medical cannabis and a distressed craft-beer rescue convert that platform into self-funding cash, or whether equity issuance remains the residual financing tool.
The mix is the tell. Distribution through the German pharmaceutical wholesaler CC Pharma is now the largest revenue line and the thinnest margin, while cannabis still supplies the fattest gross profit. International medical sales rose 34%. That growth still had to absorb more than $21 million of price compression. Beverage only grew because BrewDog, bought out of United Kingdom administration, filled a hole left by SKU cuts in the legacy United States craft book. BrewDog contributed $51 million in the spring quarter.
Adjusted earnings before interest, taxes, depreciation and amortization, the company's preferred operating-profit measure, reached $61 million. Cash from operations before working capital turned positive, but reported operating cash remained an outflow. Does the next year convert BrewDog working capital and European volume into cash that no longer requires an at-the-market share sale?